NCT06208007Recruiting
Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Source: ClinicalTrials.gov · Last updated 9 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 5 Jan 2024
- Start date
- 23 Feb 2024
- Primary completion date
- Jan 2026
- Lead sponsor
- University Medical Center Goettingen
- Diseases
- Heart failure
- NCT number
- NCT06208007
What you commit to
- Study type: Observational
- Planned participants: 150
- From 23 Feb 2024 to the primary completion date, Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant valve disease (Grade III or higher)
- History of interventional or surgical valve repair
- Respiratory diseases as a known cause for dyspnea
- Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
- History of heart transplantation
Lab values
- Left ventricular ejection fraction \< 50 %
Other
- Regional wall motion abnormalities
- Atrial flutter or fibrillation during examination
Who the study is looking for
- One or more of the following criteria:
- Age \> 60 years
- Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
- Diabetes mellitus Type I or II
- Atrial fibrillation
- Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
- BMI ≥ 30 kg/m2
- NYHA ≥ II
- E/e' \> 8
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsmedizin Göttingen Coordinator of this site? Confirm its status | Göttingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.